Glenmark Pharmaceuticals Restrained from Selling Its Type-2 Diabetes Drug
Glenmark has infringed Merck's product which contained sitagliptin phosphate monohydrate - an active ingredient that improves condition of a diabetic patient.
Glenmark has infringed Merck's product which contained sitagliptin phosphate monohydrate - an active ingredient that improves condition of a diabetic patient.
Pharma major MerckSharp and Dohme (MSD) in its plea had sought injunction against Glenmark alleging that the Indian pharma company had violated its IPR over its anti-diabetes medicines, Januvia and Janumet, by coming out with their own drugs containing the same salts.
Source-PTI
Phase I Clinical Studies For Antibody to Treat Autoimmune Disease Completed by Glenmark
Swiss subsidiary of Glenmark Pharmaceuticals announced that GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing in Netherlands.
Swiss subsidiary of Glenmark Pharmaceuticals announced that GBR 830, a novel monoclonal antibody has completed clinical phase 1 dosing in Netherlands.
Glenmark India Launches Teneligliptin for Management of Type 2 Diabetes
Teneligliptin is an advanced new third-generation oral anti-diabetic agent that suppresses' glucagon release and increases insulin to lower blood glucose levels.
Teneligliptin is an advanced new third-generation oral anti-diabetic agent that suppresses' glucagon release and increases insulin to lower blood glucose levels.
USFDA Approval Awaited By Glenmark Pharmaceuticals For 4-6 Products During This Year
The company had already got approvals for 8 products this year and awaits approval of 4-6 products from the US Food and Drug Administration.
The company had already got approvals for 8 products this year and awaits approval of 4-6 products from the US Food and Drug Administration.
